Compare Incyte Corporation (INCY) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs uniQure N.V. Ordinary Shares — how do they compare? Incyte Corporation trades at $112 (market cap $22.01B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Incyte Corporation is far larger — about 14.9× uniQure N.V. Ordinary Shares's market cap, and Incyte Corporation is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| INCY | QURE | |
|---|---|---|
Market Cap | $22.01B | $1.48B |
Volume | 2,589,484 | 2,488,780 |
Sector | Health | Health |
52-Week High | $129.93 | $70.59 |
52-Week Low | $86.17 | $9.03 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $17.52B | $728.62M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $111.57, up 0.19% on the day, with a bearish technical signal but strong fundamentals. Recent earnings beats in Q1 and Q2 2026, with EPS of $1.81 and $3.09 respectively, highlight robust profitability. The company's net income margin improved to 27.71% in 2025, and revenue growth is projected to reach $5.8 billion in 2026. Key developments include FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting long-term growth beyond JAKAFI exclusivity post-2029.
The outlook for INCY is positive, driven by pipeline advancements and a $4 billion sales target for non-JAKAFI products. However, risks include reliance on JAKAFI until 2029 and competitive pressures. Analysts maintain a buy consensus with a $132.43 price target, suggesting ~19% upside. Investors should weigh strong cash flow and valuation metrics against execution risks in pipeline commercialization.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
